Lung Transplant Recipient Exosome Phenotypes and the Risk of Primary Graft Dysfunction and Acute Lung Allograft Dysfunction is an NIH-funded, multi-center observational study. The primary objective is to identify a biomarker to predict primary graft dysfunction (PGD) and acute lung allograft dysfunction (ALAD) in lung transplant patients. Participants in this study provide serum samples prior to transplant, during the perioperative period, and at various timepoints in the year following lung transplantation.
This is a Lung Transplant Consortium U01 study. The main site for this study is at the University of Washington – Seattle, with additional sites at the University of Michigan and the University of Wisconsin – Madison. Funding for this project is anticipated to run through August of 2027.
Enrollment
A research coordinator approaches patients during evaluation week at the UW Hospital or once listed to guage interest in this study. If interested, they will go over the informed consent document and sign, but will not be enrolled until approval for listing.
Study Procedures
Blood samples are a large part of pre and post transplant care.
This study plans to collect additional blood with some of those draws.
Collection timepoints are:
- Pre-Transplant
- 24, 48, and 72 hours post transplant
- 1 month, 3 months, 6 months, 9 months, and 12 months post transplant.
This study plans to collect information from participants’ electronic medical record.
Information collected includes:
- Age, sex, and ethnicity
- Health, medical, surgical, and social history
- Lab results
- Transplant details
- Medications and treatments received
- Complications or infections, lung function, imaging studies, and biopsy results